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In this review, we trace the concept and potential functional role of regulatory idiotypes
in the immune response to human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus, and hepatitis C virus (HCV). A major idiotype involved in these viral
infections is recognized and defined by a murine monoclonal antibody (1F7). Antibodies
expressing the idiotype defined by 1F7 are dominant in HIV-1 infection and are also
found on many broadly neutralizing antibodies against HIV-1. This regulatory idiotypic
axis offers opportunities for exploitation in vaccine development for HIV-1, HCV, and
other chronic viral infections.
Keywords: idiotype, 1F7, HIV, SIV, HCV

ANTI-IDIOTYPIC ANTIBODIES AND IMMUNE REGULATION
Oudin and Jerne are the founders of the Idiotype Concept (1, 2). They “discovered” that one antibody
could recognize another antibody as an individual and unique member of the immune system. The
uniqueness of an antibody lies in the variable region of heavy and light chains and has been named
idiotype. Essential insight into the Idiotypic network has emerged from studies on the immune
response of mice to phosphorylcholine (PC) [for review, see Ref. (3)]. Evidence that idiotype–antiidiotype interactions may play a role in the regulation of the immune response came in part from
the observation that auto-anti-idiotypic antibodies appear during an immune response to PC (4, 5).
Similar evidence of auto-anti-idiotypic antibodies was later discovered in human immunodeficiency
virus type 1 (HIV-1)-infected individuals who had antibodies against the 1F7 idiotype (6).
The utility of anti-idiotypic antibodies as immune regulatory molecules was initially demonstrated by Cosenza and Kohler who showed that an anti-idiotype antibody suppressed the response
to PC (7, 8). Eichmann and Rajewski later suggested that anti-idiotype antibodies could be used as
vaccines (9). In the following decades, anti-idiotypic antibodies have been investigated and probed
as therapeutic antibodies in a variety of infectious diseases and malignancies. These anti-idiotypes
were used successfully as surrogate antigens, termed Ab2beta, internal image or network antigen,
thus replacing the original antigens used as therapeutic vaccines (10).
Anti-idiotypic antibodies were defined as Ab2alpha, Ab2beta, and Ab2gamma, reflecting their
biological function as therapeutic antibodies. While Ab2alphas are non-internal images, which are
non-biologically effective antibodies, Ab2gammas are non-internal images, which are biologically
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effective antibodies. Therefore, Ab2beta and Ab2gamma, being
both biological effective as therapeutic antibodies, were integrated under the term network antigens (11). The term “idiotype”
is used to refer to the entire collection of unique idiotopes within
the variable region of a monoclonal antibody (mAb), whereas the
term “idiotope” refers to a single determinant recognized within
the variable region of an antibody.
Idiotypes expressed on anti-pathogen antibodies might also
be utilized as disease markers (12). In the following, we will
review the recent progress or lack thereof in the utilization of
anti-idiotypes as therapeutic antibodies or disease markers. We
will focus on HIV-1 and hepatitis C virus (HCV) infection as both
HIV-1 and HCV can lead to cancer in late stages of infectious
disease (13, 14).

mononuclear cells (PBMC) from HIV-1-infected individuals
with 1F7-induced apoptosis of CD4+ and CD8+ T cells and the
1F7 mAb selectively blocked cytotoxicity of CD8+ T cells from
HIV-1-infected individuals (20, 21). The 1F7 idiotype is also
expressed on antibodies against the envelope glycoprotein of
simian immunodeficiency virus (SIV)- and chimeric simianhuman immunodeficiency virus (SHIV) in infected rhesus
monkeys (22, 23). As such, the impact of idiotypic regulation
through targeting the 1F7 idiotype was explored in the SHIVIIIB infection model (24, 25). Suppressing expression of the
1F7 idiotype through administration of the murine 1F7 mAb
to macaques chronically infected with SHIV-IIIB increased
the potency and breadth of neutralizing antibodies, with an
increase in neutralization titer against HIV-IIIB and crossneutralization of HIV-MN as tested by syncytium forming
microassay (25). This was interpreted as a result of relieving
clonal dominance of the 1F7 idiotype in the humoral response
to SHIV, such that new antibodies could arise.
The murine 1F7 mAb has been designated as an Ab2delta
antibody to distinguish it from Ab2alpha, Ab2beta, and
Ab2gamma anti-idiotypes (26). Recently, we found that this
anti-idiotypic clone also stained local SIV gp41-antibodies
emerging in naive macaques after intravenous vaccination with
SIVmac239 delta Nef and vaginal challenge with wild type SIV
(27). Local antibody production in the genital tract correlated
with the maturation of protection against high-dose pathogenic
SIV vaginal challenge (28).

EXPRESSION OF THE 1F7 IDIOTYPE ON
ANTIBODIES AGAINST IMMUNE
DEFICIENCY-CAUSING RETROVIRUSES
Several HIV infection-related anti-idiotype studies preceded 1F7
anti-idiotype research. These previous studies demonstrated that,
in contrast to 1F7, some anti-idiotypes could be used as surrogate
antigen to stimulate immune responses against HIV.
Morrow et al. demonstrated that anti-idiotypic antisera
against a mAb specific for a p24 gag region epitope detected a
common interspecies idiotype associated with anti-HIV response
(15). Kang et al. produced an anti-idiotypic mAb (3C9) related
to gp120-affinity purified human anti-gp120 antibodies directed
against the conserved CD4 attachment site of gp120. It was
subsequently shown that immunization with anti-idiotype 3C9
elicited broadly neutralizing antibodies (BnAbs) in naive, nonHIV-infected monkeys (16).
The murine monoclonal antibody defining the 1F7 idiotype,
and named 1F7, was originally raised against pooled human antibodies against HIV-1, subcloned, and further selected by ELISA
against specific anti-HIV-1 antibodies captured by HIV-1 proteins gp120 and p24 (17). Pooled human immunoglobulin from
non-HIV-1-infected individuals (IVIG) was used as negative
control in the selection process. Further investigation revealed
that human monoclonal anti-gp120, and anti-p24 antibodies, as
well as anti-HIV-1 human serum antibodies, share the common
idiotype/clonotype 1F7 (18).
Subsequent research identified a region (FR3–CDR3) on
three human mAb directed against gp120 or p24 that bound
to the murine anti-1F7 mAb, allowing production of a peptide
mimicking the idiotypic region. Design of the peptide was
based on the molecular recognition theory. As such, regions of
inverse hydropathy between the variable sequence of the anti1F7 and the human mAb, which are assumed to be involved
in the idiotype–anti-idiotype contacts, were selected for the
peptide design (19). Human anti-HIV-1 serum antibodies
from a variety of HIV-1-infected individuals bound to this
peptide, indicating an auto-anti-idiotypic humoral immune
response to the 1F7 idiotype (6). Further evidence of a biological role for the 1F7 idiotype in HIV-1 infection was provided
by studies of cellular immunity. Culture of peripheral blood

Frontiers in Oncology | www.frontiersin.org

EXPRESSION OF THE 1F7 IDIOTYPE ON
ANTI-HCV ANTIBODIES
Since 1F7 is a widely shared idiotype/clonotype, some crossreactivity with antibodies directed to similar structures is not
surprising. Parallel research revealed that the 1F7 idiotype
is also expressed on antibodies against a number of different
HCV proteins (29). Since approximately 20% of HCV-exposed
individuals spontaneously clear HCV infection and chronic HCV
infection can be cured through treatment, this finding enabled
investigation of a possible relationship between expression levels
of antibodies bearing the 1F7 idiotype and development or
persistence of chronic infection (30). Direction of anti-pathogen
immune responses along pathways with inherent limitations as
to the potency of induced antibodies was previously suggested
as a mechanism by which chronic pathogens may have evolved
to subvert the immune response (29, 31, 32). For example, if the
dominant antigens of the pathogen have some similarity to self
antigens, then conserved aspects of immunological self-tolerance
could limit the efficacy of responses against the pathogen (33,
34). In the context of idiotypic regulation of the immune system,
we have also proposed that chronic pathogens may have evolved
to stimulate immune responses along conserved idiotypic axes
defining areas of high network connectivity (29, 30). Stimulating
B cells with extensive internal connectivity would propagate high
levels of idiotypic recognition with reciprocal stimulation of
potentially irrelevant B cell clones and favor chronic oligoclonal
activation over the focused selection of high-affinity antibodies
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with effective potency against the pathogen. Davtyan et al.
compared levels of HCV core-specific antibodies expressing the
1F7 idiotype in HCV-exposed individuals who either cleared
infection or progressed to chronic infection. Levels of 1F7 idiotype expression were significantly higher on anti-HCV core
antibodies from HCV-exposed individuals who progressed to
chronic infection than on the anti-HCV core antibodies of those
who spontaneously cleared HCV infection (30). In addition, a
hierarchy of 1F7 idiotype expression levels was discernable in
total circulating IgG and IgM with chronic infection greater
than spontaneous clearance greater than HCV non-exposed
individuals (30). The concept that pathogens establishing chronic
infection, despite strong humoral responses, have evolved to
select antibodies along a common idiotypic axis of the immune
network represented by the 1F7 idiotype may also relate to previous studies of a public idiotype termed 16/6. Elevated levels of
the 16/6 idiotype occur in autoimmune disease and microbial
infection, while injection of mice with antibodies bearing the
16/6 idiotype induces chronic immune activation and systemic
lupus erythematosus (SLE)-like symptoms (35–38). In this case,
there also appears to be a link between induction of antibodies
along a common idiotypic axis demarcated by the 16/6 idiotype,
immune activation, and autoreactivity. Based on these studies,
the concept of pathogenic idiotypes arose, where idiotypes such
as 16/6 identify antibodies that are directly autoreactive or have
the capacity to disturb idiotypic regulation in ways that promote
chronic activation and development of autoimmunity (39, 40).
Identification of the distinct B1 B cell subset as the primary source
of neonatal and natural antibodies with both a high frequency
of autoreactivity and high connectivity apparently separated the
B cell repertoire into subdivisions engaged in developmental
regulation versus protection against pathogens. Although B1 B
cells are distinguished by their developmental pathway, T cell
independence and scarcity of somatic hypermutation or isotype
switching, their use of the same set of germ-line antigen receptor
genes as B2 B cells guarantees some level of idiotypic overlap
between the two repertoires.
The fraction of CD5-expressing (B1) and CD5-negative B cells
carrying the 1F7 idiotype was measured in uninfected controls
and individuals with chronic HCV infection by flow cytometry.
While there was expansion of 1F7-expressing B cells in both subsets in chronic HCV infection, it was clearly skewed toward the
CD5-expressing subset with up to 30% of B1 B cells expressing
the 1F7 Id in some HCV-infected individuals compared to <2%
in uninfected controls (30). Despite this marked effect of HCV
infection on expansion of B1 B cells expressing the 1F7 idiotype,
the majority of circulating antibodies against HCV and HIV-1
that express the 1F7 idiotype have undergone secondary receptor
modification and, therefore, appear to originate from the B2 B cell
subset (17, 18, 22, 23, 29).

independent roles, different interactions with T cells, level of
connectivity, and frequency of autoreactivity. Chronic infection allows for the investigation of the long-term influence that
selective expression of a common idiotype has on evolution
of antibodies against an infectious agent. Despite demonstrations of anti-HIV-1 antibodies against different proteins and
across numerous HIV-1-infected donors carrying the 1F7
idiotype; until recently, little attention was paid to the breadth
of these idiotypic antibodies (17, 18). An ideal starting point
for assessing the breadth of 1F7-idiotypic antibodies is to
screen anti-HIV-1 BnAbs for expression of the idiotype as the
process of antibody evolution within a common idiotypic space
is intricately illustrated in the development of BnAbs against
HIV-1. Anti-HIV-1 BnAbs are a subset of antibodies capable
of neutralizing wide arrays of HIV-1 isolates, both within and
across viral subtypes (41). These antibodies have great potential as prophylactics against HIV-1, as upon passive transfer or
gene delivery to macaques and humanized mice they provide
protection from challenges with SHIV and HIV-1, respectively
(42–46). Approximately 20% of HIV-1-infected individuals
develop antibodies with broadly neutralizing activity against
different HIV viruses (47). The HIV-1 BnAbs are unique in
that the variable regions have undergone extensive levels of
somatic hypermutation not replicated using currently available
vaccine formulations (48). Germ-line precursors of the HIV-1
BnAb generally bind HIV-1 envelope glycoproteins poorly, if
at all (49). As such, selection of such antibodies may initially
require non-HIV-1 antigens (50). Fine-tuning the anti-HIV-1
specificity of these antibodies, as well as the generation of
broad neutralization capacity, would likely require additional
rounds of selection and somatic hypermutation. To assess the
breadth of 1F7-idiotypic antibodies, Parsons et al. screened
six well-characterized HIV-1 BnAbs (i.e., 2G12, b12, VRC01,
2F5, 4E10, and Z13e1) for expression of the 1F7 idiotype via
ELISA, and demonstrated the presence of the 1F7 idiotype on
all six antibodies (51). Given that 1F7-idiotypic antibodies
are observed within a majority of HIV-1-infected individuals,
but BnAbs are only detected in approximately 20% of infected
individuals, this observation raised questions about how
BnAbs develop from antibodies within the relatively common
1F7-idiotypic node.
Previous studies demonstrated that anti-HIV-1 antibody
responses are subject to a form of original antigenic sin,
known as repertoire freeze and deceptive imprinting (32, 52,
53). Establishment of antibodies against the contemporaneous autologous virus initiates this phenomenon during acute
infection. Although the virus rapidly escapes to evade the
abilities of these antibodies to suppress viral replication, B-cells
carrying B-cell receptors (BCR) corresponding to these antibodies sufficiently recognize the escaped virus to be selected
to undergo further rounds of somatic hypermutation (or at
least keep responding to subsequent antigenic challenges).
The continuous reselection of these early-established B-cell
responses sustains the early-induced antibody response at the
expense of novel B-cell responses more specific for the contemporaneous autologous viruses of chronic infection. Evidence of
this phenomenon includes maintenance of skewed κ/λ ratios

ANTI-HIV-1 ANTIBODY BREADTH WITHIN
THE 1F7 IDIOTYPE
Engagement of both the B1 and B2 subsets in response
to an infection is unusual with respect to their perceived
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throughout infection, restricted and biased variable region
gene usage throughout infection and persistence of antibody
clones recognizing earlier viral variants, despite escape many
months prior (54–57). Given the occurrence of repertoire freeze
during HIV-1 infection, Parsons et al. hypothesized that BnAbs
develop from 1F7-idiotypic antibodies established during early
infection through multiple rounds of selection and somatic
hypermutation (51). To assess this possibility, they screened
serial plasma samples from six HIV-infected donors over time
points ranging from acute through chronic infection to determine if 1F7-idiotypic antibodies arise during acute infection
and are sustained throughout infection. Indeed, 1F7-idiotypic
antibodies were detected in plasma samples collected within the
first 3 months of HIV-1 infection, and these antibodies were
expanded and sustained with longer duration of infection. This
observation suggests that 1F7-idiotypic antibodies engaged
during acute infection and sustained throughout infection in
an idiotypic repertoire freeze are driven through repeated selection and somatic hypermutation to develop into BnAbs. This
putative route to BnAb development is consistent with pathways
hypothesized by others and has implications for designing
BnAb-inducing vaccines.
Consistent with the hypothesis that BnAbs develop through
repeated selection and somatic hypermutation of 1F7-idiotypic
antibodies induced early in infection, Liao et al. recently demonstrated directly that antibodies capable of neutralizing a broad
range of HIV-1 isolates develop as a result of repeated selection
and mutation of antibodies by constantly evolving autologous
HIV-1 (58). Haynes et al. hypothesized that BnAbs might be
inducible through vaccination strategies that sequentially expose
vaccine recipients to HIV-1 envelope antigens selected on the
basis of binding to chronologically relevant antibody isolates,
derived from HIV-1-infected donors that developed BnAbs (59).
This vaccination strategy might benefit from inclusion of a prime
and/or boost with F(ab)2 of the murine monoclonal anti-idiotypic
antibody used to detect the 1F7 idiotype in in vitro assays. As
anti-HIV-1 BnAbs appear to be selected from the 1F7-idiotypic
repertoire, a prime with the anti-1F7 F(ab)2 should focus the
B-cell response of later immunizations with relevant HIV-1
envelope antigens within the relevant B-cell repertoire. Similarly,
boosts with anti-1F7 F(ab)2 might have the benefit of increasing
the frequency of the relevant B-cell responses induced by the
sequential vaccination strategy.
In addition to the ability of BnAb to prevent HIV-1 infection, non-neutralizing anti-HIV-1 antibodies have also recently
gained attention as potentially protective moieties. Indeed, the
ability of non-neutralizing antibodies to mediate antibodydependent cellular cytotoxicity (ADCC) against HIV-1 was
linked to the partial success of the RV144 Thai vaccine trial
(60–62). Similarly, the ability of antibodies to mediate ADCC
has been linked to protection against infection with pathogenic
SIV challenge in macaques immunized with live-attenuated SIV
(63). The ADCC competency of antibodies passively transferred
via breast milk from HIV-1-infected mothers to their children
was also associated with a lower likelihood of mother-to-child
transmission (64). The breadth of these non-neutralizing ADCC
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competent antibodies, defined as the ability of such antibodies
to trigger ADCC against target cells expressing HIV-1 envelope
antigens from different viral subtypes, appears important to
their protective capacity. In fact, a recent assessment of the
breadth of ADCC antibodies from HIV-1-infected controllers
and progressors demonstrated more breadth in controllers
(65). Therefore, it is likely imperative to understand the origin
of HIV-1 envelope binding antibodies with broad recognition profiles. In this regard, Parsons et al. recently assessed
expression of the 1F7 idiotype on broadly reactive anti-HIV-1
antibodies from individuals infected with HIV-1 subtype B that
cross-reacted with HIV-1 envelopes (i.e., gp140) from subtype B,
A, and AE viral isolates (66). The 1F7 idiotype was detected on
antibodies binding to each HIV-1 subtype envelope, suggesting
broad recognition within the anti-HIV-1 1F7-idiotypic node.
Similarly, when expression of the 1F7 idiotype was assessed on
subtype B envelope (i.e., gp120)-binding anti-HIV-1 antibodies
derived from individuals infected with non-subtype B viruses,
the idiotype was observed on antibodies from 15/19 donors.
Together with data regarding 1F7-idiotypic expression on antiHIV-1 BnAbs, the expression profile of the 1F7 idiotype on antiHIV-1-binding antibodies with broad recognition capabilities
suggests that vaccines focusing anti-HIV-1 antibody responses
within the 1F7-idiotypic repertoire can achieve a substantial
breadth of HIV-1 recognition.
How best to exploit the immense breadth available within the
1F7-idiotype domain remains an open question. The potential
breadth of this node may be dramatically narrowed by repertoire
freezes induced by HIV-1 infection itself or by vaccination with
single strains. Recently, Kohler discussed that the establishment
of such repertoire freezes results in “back-boosts” upon exposure
to antigenically related, yet distinct, antigens, as would be the case
upon challenge with a different viral strain than that utilized for
vaccination (67). He further proposed utilizing the full breadth
of the 1F7-idiotypic repertoire by “forward-boosting” or priming
the entire 1F7 repertoire prior to exposure to any HIV-1 antigens.
Future research should evaluate the ability of such a “forwardboosting” protocol to establish broadly reactive anti-HIV-1
antibodies capable of mediating potent effector functions against
HIV-1 or HIV-1 infected cells (see Figure 1 depicting the forward
boosting strategy).

SUMMARY
The concept and significance of dominant idiotypes surfaced
more than 40 years ago, and the practical value of internal
image antibodies or network antigens as immunogens was
realized shortly afterwards. Regulatory idiotypes, the levels of
which might reflect immune trajectories toward autoimmunity
or immune deficiency, were proposed in the mid 1980s and
continue to be studied today in autoimmunity, cancer, and
infectious disease. In this review, we described how antibodies against multiple antigens of retroviruses capable of causing
immune deficiency syndromes, including HIV-1, SIV, and SHIV,
and also antibodies against HCV share a common idiotype
designated 1F7. Expression of this idiotype is associated with a
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FIGURE 1 | Overcoming deceptive imprinting through forward boosting. The left side of the diagram represents the B cell response to HIV-1 upon natural
exposure to HIV-1 or immunization with an HIV-1 vaccine construct. This exposure results in a subset of naive B cell clones (N), which carry B cell receptors capable
of binding HIV-1 antigens, being selected to undergo differentiation into memory B cells (M). This initial selection process induces a phenomenon known as
deceptive imprinting. This phenomenon results in a reselection of previously selected B cell clones, at the expense of naive B cells carrying novel antigen-binding B
cell receptor specificities, upon exposure to mutated HIV-1 or alternative HIV-1 vaccine constructs. The right side of the diagram depicts the forward-boosting
strategy. This strategy predicts priming 1F7-idiotypic B cell clones (i.e., those expressing orange tipped B cell receptors), which exhibit broad HIV-1 reactivity, will
establish a larger repertoire of B cell clones that can contribute to the anti-HIV-1 antibody response following future exposure or immunization. Upon future exposure
to HIV-1 or an HIV-1 vaccine construct boosting of a subset of the memory B cells established from the initial anti-1F7-idiotype prime will be observed. Additional
anti-1F7-idiotype primed clones should be boosted, and not impeded by deceptive imprinting, upon exposure to cognate antigens on mutated HIV-1 or alternative
HIV-1 vaccine constructs. The bottom of the diagram, on both the left and right sides, demonstrates that selected B cell clones contribute to the antibody response
upon becoming long-lived plasma cells (P).

form of clonal dominance that appears to restrict development
of neutralizing antibodies against contemporaneous infecting
strains of HIV-1 and imposes a trajectory toward chronic infection with HCV. However, BnAbs that develop against HIV-1
do bear the 1F7 idiotype, indicating that the same idiotypic
axis accommodating clonal dominance and original antigenic
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sin also accommodates antibody evolution toward the highly
mutated progeny capable of neutralizing diverse strains of HIV1. Learning how to exploit this axis selectively to prime for the
development of BnAbs in advance of viral exposure may be a
key to more effective vaccination against chronic viruses, such
as HIV-1, HCV, and others.
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